| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6169366 | The Breast | 2016 | 6 Pages |
Abstract
The association of everolimus and exemestane has confirmed to be a safe and effective treatment for endocrine sensitive MBC patients even in routine clinical practice. The rate of treatment discontinuation due to toxicity is low and none association between previous number of treatments and response or between toxicity and response was found.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
L. Moscetti, P. Vici, T. Gamucci, C. Natoli, E. Cortesi, P. Marchetti, D. Santini, R. Giuliani, I. Sperduti, M. Mauri, L. Pizzuti, M.L. Mancini, M.A. Fabbri, V. Magri, L. Iezzi, V. Sini, L. D'Onofrio, L. Mentuccia, E.M. Ruggeri,